Showing 3191-3200 of 3314 results for "".
- Editas Medicine Announces FDA Acceptance of IND Application for LCA10 Treatment EDIT-101https://modernod.com/news/editas-medicine-announces-fda-acceptance-of-ind-application-for-lca10-treatment-edit-101/2476163/Editas Medicine announced that the FDA has accepted the company’s investigational new drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). “The FDA’s acceptance of our IND for
- Bayer to Cut 12,000 Jobs, Exit Vet Unit Amid Drag From Suitshttps://modernod.com/news/bayer-to-cut-12000-jobs-exit-vet-unit-amid-drag-from-suits/2479631/Bayer announced Thursday that it will cut around 1,250 jobs from its pharmaceutical division as part of a wider staff-reduction plan that will lead to the loss of about 12,000 positions from its global workforce of 118,200 employees by the end of 2021. The streamlining is part of an overhaul unde
- New Data Indicate that EyeMax Mono Offers Significant Improvement in Visual Function in Dry AMD Patientshttps://modernod.com/news/new-data-indicate-that-eyemax-mono-offers-significant-improvement-in-visual-function-in-dry-amd-patients/2479640/LEH Pharma announced new data published in the Journal of Refractive Surgery, suggesting that EyeMax Mono offers benefits in terms of visual function for people with dry age-related macular degeneration (AMD). EyeMax Mono is an IOL specifically designed to deliver improved visual outcome
- EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretaryhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-ron-honig-esq-as-svp-general-counsel-company-secretary/2479642/EyePoint Pharmaceuticals announced the appointment of Ron Honig, Esq., as Senior Vice President, general counsel, and company secretary, effective immediately. In this new role, Mr. Honig will the oversee the company’s legal activities, including the legal aspects of licensing, compliance, strate
- SECO 2019 Puts Spotlight On Vision Industry Trendshttps://modernod.com/news/seco-2019-puts-spotlight-on-vision-industry-trends/2479643/SECO 2019 will lead the conversation on the latest vision industry trends when SECO 2019 takes place February 20-24, 2019 in New Orleans. From the latest technological innovations in eye and healthcare to up-and-coming eyewear products, SECO 2019 is where the optometric community of professional
- Georgia Eye Associates Affiliates with EyeSouth Partnershttps://modernod.com/news/georgia-eye-associates-affiliates-with-eyesouth-partners/2479657/EyeSouth Partners has announced that it has completed a strategic partnership with Georgia Eye Associates, expanding its presence into the Lawrenceville and northeast Atlanta regions. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower
- Envision Research Institute Announces Search for Post Doctoral Fellows to Study Low Visionhttps://modernod.com/news/envision-research-institute-announces-search-for-post-doctoral-fellows-to-study-low-vision/2479664/The Gigi & Carl Allen Envision Research Institute (ERI) is now calling for letters of intent to apply for its next round of postdoctoral research fellowships. Launched in 2015 with a goal to restore function to those who are blind and visually impaired, the ERI provides access to funds, facil
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi